Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
V$438.91+2.32(+0.53%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.90+0.91(+1.14%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$759.97-35.49(-4.46%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$289.81+2.51(+0.87%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.92-1.36(-2.33%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,460.30-35.84(-2.40%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.84+0.98(+0.96%)Transaction in Own Shares8:00:53 AM ETIBM$256.39+2.07(+0.81%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$634.31+4.31(+0.68%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$289.81+2.51(+0.87%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.55+5.04(+1.44%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.39+2.07(+0.81%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$196.95-3.34(-1.67%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.55+5.04(+1.44%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.65+0.43(+0.15%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.30-4.40(-2.56%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.50+1.70(+0.31%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ET

CRBP · NASDAQ

Corbus Pharmaceuticals Holdings, Inc.

$3.55 -0.04 (-1.11%)

Company overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on developing immune modulators for immuno-oncology and fibrosis diseases. Its pipeline includes lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), currently in a Phase II clinical trial for systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for treating cancer and fibrosis by inhibiting transforming growth factor β (TGFβ) activation; and CRB-602, an anti-αvβ6/αvβ8 mAb that blocks TGFβ activation for fibrotic diseases.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$68.7M
Employees
36
Headquarters
Norwood, MA
Website
corbuspharma.com
CEO
Yuval Cohen
Listed
October 27, 2014
P/E
-0.54
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$149,000
Operating income
-$89.8M
EBITDA
-$85.7M
Net income
-$84.5M
EPS
-$6.60
Total assets
$144M
Total debt
$1.2M
Earnings yield
-185.92%

Price chart

3.205.718.2310.7413.25
CRBP 1D NASDAQ O3.97H4.10L3.57C3.59-0.28 (-7.24%)Vol1.74M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? Zacks Investment Research
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' Benzinga
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Announces Positive Topline Data from GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Benzinga
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals to Host Conference Call to Discuss GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript Seeking Alpha
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study MarketBeat
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript Seeking Alpha
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Press release Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 GlobeNewswire
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge Benzinga
CRBPCorbus Pharmaceuticals Holdings, Inc. Stock news Assenagon Asset Management S.A. Has $1.53 Million Holdings in Corbus Pharmaceuticals Holdings, Inc. $CRBP Defense World
See more
FAQ

Questions about Corbus Pharmaceuticals Holdings, Inc.

What does Corbus Pharmaceuticals Holdings, Inc. do?
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on developing immune modulators for immuno-oncology and fibrosis diseases. Its pipeline includes lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), currently in a Phase II clinical trial for systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for treating cancer and fibrosis by inhibiting transforming growth factor β (TGFβ) activation; and CRB-602, an anti-αvβ6/αvβ8 mAb that blocks TGFβ activation for fibrotic diseases.
What is CRBP's market cap?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a listed stock with a live quote. The latest market cap on this page is $68.7M.
Where is Corbus Pharmaceuticals Holdings, Inc. headquartered?
Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, MA.
How do I get CRBP news from the API?
Call GET /v1/news?tickers=CRBP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CRBP news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CRBP, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CRBP price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs